source
- Pharma pours billions into bispecifics, ADCs and cell therapies despite limited clinical proofThe article notes that emerging drug formats such as bispecific antibodies, antibody‑drug conjugates and cell therapies have yet to demonstrate clear clinical success, yet pharmaceutical firms cont…
- Iambic Therapeutics raises $150 million in IPO, begins Nasdaq trading under ticker IAMIambic Therapeutics, an AI-driven drug discovery startup, completed an initial public offering that raised $150 million. The company sold about 9.4 million shares at $16 each and will start tradin…